Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Market Closed 05-29 16:00:00 EDT

31.43

-0.27

-0.85%

盘后31.43

+0.000.00%

17:40 EDT

High32.00	Low31.09	Vol494.67K
Open31.79	D1 Closing31.70	Amplitude2.87%
Mkt Cap2.47B	Tradable Cap2.22B	Total Shares78.49M
T/O15.56M	T/O Rate0.70%	Tradable Shares70.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":31.43,"timestamp":1780084800000,"preClose":31.7,"halted":0,"volume":494672,"hourTrading":{"tag":"盘后","latestPrice":31.43,"preClose":31.43,"latestTime":"17:40 EDT","volume":56289,"amount":1769161.8601,"timestamp":1780090858284,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.008517350157728693,"floatShares":70781700,"shares":78492100,"eps":-4.267422,"marketStatus":"Market Closed","change":-0.27,"latestTime":"05-29 16:00:00 EDT","open":31.79,"high":32,"low":31.09,"amount":15562203.03808,"amplitude":0.028707,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.267422,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":31.7,"preHourTrading":{"tag":"盘前","latestPrice":31.83,"preClose":31.7,"latestTime":"09:29 EDT","volume":2077,"amount":65902.861064,"timestamp":1780061399999,"change":0.13,"changeRate":0.004101,"amplitude":0.053628},"postHourTrading":{"tag":"盘后","latestPrice":31.43,"preClose":31.43,"latestTime":"17:40 EDT","volume":56289,"amount":1769161.8601,"timestamp":1780090858284,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7182385416733112,"impliedVol":0.3568,"impliedVolPercentile":0.1554},"requestUrl":"/m/hq/s/CLDX","defaultTab":"news","newsList":[{"id":"2638369406","title":"Celldex publishes investor presentation highlighting barzolvolimab late-stage urticaria trials and broader mast cell disease pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2638369406","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638369406?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:11","pubTimestamp":1779981105,"startTime":"0","endTime":"0","summary":"Celldex publishes investor presentation highlighting barzolvolimab late-stage urticaria trials and broader mast cell disease pipeline. Celldex outlined late-stage plans for barzolvolimab , a KIT-antagonist antibody targeting mast cell-driven inflammatory diseases.Phase 3 CSU program enrollment finished 6 months ahead of guidance; topline data expected Q4 2026; BLA filing planned for 2027.Two Phase 3 CSU trials plan 1,939 patients across 43 countries; primary endpoint is mean change in UAS7 at Week 12.Phase 3 ColdU and symptomatic dermographism study initiated December 2025 under a global chronic inducible urticaria program.Phase 2 barzolvolimab studies in prurigo nodularis and atopic dermatitis are fully enrolled; topline data expected summer 2026 and late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes onl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL3L44zF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780729","title":"Celldex Therapeutics Is Maintained at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780729","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780729?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:36","pubTimestamp":1778679360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 09:36 ET (13:36 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PGF","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635065322","title":"U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic","url":"https://stock-news.laohu8.com/highlight/detail?id=2635065322","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635065322?lang=en_us&edition=fundamental","pubTime":"2026-05-13 15:31","pubTimestamp":1778657497,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Aecom, Humana, MosaicMay 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aecom, Humana and Mosa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL4N41Q0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADI","CASY","JNJ","CDNL","AMDG","FERG","AMD","GIS","BLLN","COHR","ARVN","EOG","AMDD","ACM","ANAB","DAMD","HUM","AURA","NTLA","AMDL","CSTL","COHX","AMDW","BRCB","AVT","BOOT","XYZ","AMDU","ADC","CGBD","BXP","EPRT","AMYY","AMDY","CLDX","JAN","IBP","HASI","ANDG","AIZ","DCO","AMBQ","ADSK","AMTM","ARMK","ARW","CRBG","XYZG","JXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634623103","title":"The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2634623103","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634623103?lang=en_us&edition=fundamental","pubTime":"2026-05-12 02:17","pubTimestamp":1778523421,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics recently reported first-quarter 2026 results, with revenue falling to US$15,000 from US$695,000 a year earlier and net loss widening to US$78.69 million, while accelerating investment in late-stage development of its lead antibody barzolvolimab.\nAt the same time, Celldex completed Phase 3 enrollment for barzolvolimab in chronic spontaneous urticaria six months ahead of plan and raised about US$345 million in a follow-on offering, extending its funding runway for ongoing...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/the-bull-case-for-celldex-therapeutics-cldx-could-change-fol-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/the-bull-case-for-celldex-therapeutics-cldx-could-change-fol-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ARTY","AGIX","BK4528","BK4543","BK4023","AI","CHAT","BK4588","BK4587","CLDX","BK4139","AIYY","BK4551","BK4585","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450349","title":"Celldex Therapeutics Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450349?lang=en_us&edition=fundamental","pubTime":"2026-05-08 22:53","pubTimestamp":1778251980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 10:53 ET (14:53 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459222","title":"Celldex Therapeutics Inc  expected to post a loss of $1.15 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459222","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459222?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:55","pubTimestamp":1778244906,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics Inc  expected to post a loss of $1.15 a share - Earnings Preview Celldex Therapeutics Inc CLDX.OQ CLDX.O is expected to  show a rise in quarterly revenue when it reports  results ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432955","title":"Celldex price target raised to $48 from $45 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432955","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432955?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:20","pubTimestamp":1778235655,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Celldex (CLDX) to $48 from $45 and keeps an Overweight rating on the shares. Published first on TheFly –...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-price-target-raised-to-48-from-45-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-price-target-raised-to-48-from-45-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633102660","title":"Analysts Are Bullish on These Healthcare Stocks: Tectonic Therapeutic (TECX), Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633102660","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633102660?lang=en_us&edition=fundamental","pubTime":"2026-05-08 09:30","pubTimestamp":1778203813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tectonic Therapeutic (TECX), Celldex (CLDX) and Sile...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-tectonic-therapeutic-tecx-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-tectonic-therapeutic-tecx-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","LU0128526141.USD","BK4137","BK4588","BLSX","CLDX","BK4581","BK4139","BK4585","LU0029874061.USD","BLSG","TECX","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633174572","title":"Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633174572","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633174572?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:28","pubTimestamp":1778185693,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.20) by 1.67 percent. This is a 45.68 percent decrease over losses of $(0.81) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52391237/celldex-therapeutics-q1-eps-1-18-beats-1-20-estimate-sales-15-000k-miss-972-222k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633617609","title":"Celldex Q1 net loss widens to $78.7 million; R&D expenses rise to $73 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633617609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633617609?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:06","pubTimestamp":1778184377,"startTime":"0","endTime":"0","summary":"Celldex posted a Q1 net loss of USD 78.7 million, or USD 1.18 per share, widening from USD 53.8 million, or USD 0.81 per share, year earlier.Revenue fell to USD 15,000 from USD 695,000, on lower services performed under manufacturing and R&D agreements with Rockefeller University.R&D expense climbed to USD 73 million from USD 52.6 million, driven by higher barzolvolimab clinical trial and contract manufacturing costs plus increased headcount.Cash, cash equivalents and marketable securities totaled USD 451.5 million at March 31, down from USD 518.6 million at Dec. 31, as USD 65.6 million was used in operating activities.Enrollment finished six months ahead of guidance in Phase 3 barzolvolimab CSU trials with topline data expected in Q4 2026; Celldex raised USD 345 million in gross proceeds in an April follow-on and expects cash plus about USD 323.9 million in net proceeds to fund operations through 2028.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL2qVDdc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014005.SGD","BK4588","BK4139","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","BK4585","CLDX","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633017522","title":"Celldex Therapeutics Q1 Operating Income USD -84.435 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633017522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633017522?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184064,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX6ACA43:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633176460","title":"Celldex Reports First Quarter Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633176460","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633176460?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:01","pubTimestamp":1778184060,"startTime":"0","endTime":"0","summary":"Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3290499/24180/en/Celldex-Reports-First-Quarter-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","AEC","BK4096","CLDX","BK4132","BK4156","BK4139","PN","TSLP","SD","POM","AD","BK4175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629028854","title":"Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2629028854","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629028854?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:13","pubTimestamp":1776863611,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics stock snapshot\nCelldex Therapeutics (CLDX) has drawn investor attention after recent gains, with the share price at $34.25 and total return figures of 10.8% over the past month and 30.9% over the past 3 months.\nSee our latest analysis for Celldex Therapeutics.\nShort term momentum has been firm, with a 30 day share price return of 10.8% and a 90 day gain of 30.9%, while the 1 year total shareholder return of 76.6% reflects a strong recent run compared with its longer term...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/assessing-celldex-therapeutics-cldx-valuation-after-strong-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628226027","title":"BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2628226027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628226027?lang=en_us&edition=fundamental","pubTime":"2026-04-20 23:53","pubTimestamp":1776700380,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Adobe, Agios, QXOWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://refi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nL6N41310S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKTG","JPMO","WHR","ASTX","MRVL","QXO","XOMZ","HLXX","DVN","HL","USAR","FRMI","GTLB","AMZN","NKTR","CDE","LION","CMPS","ADBE","GHRS","SF","XOM","USAW.SI","SOC","AGIO","ASTS","MVLL","SIDU","SRFM","FCXG","DFTX","JEF","RBC","ASTN","SCCO","OKTA","GLSI","CVX","PASG","FCX","BLD","OXY","META","ATAI","NEM","CLDX","CLF","AAL","BIIB","CCL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628064729","title":"A Top Wall Street Analyst ‘Can’t Ignore’ Celldex Stock (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628064729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628064729?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:19","pubTimestamp":1776694757,"startTime":"0","endTime":"0","summary":"Celldex stock was on the move Monday alongside an upgrade and increased price target from a top Wall Street analyst.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/a-top-wall-street-analyst-cant-ignore-celldex-stock-cldx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/a-top-wall-street-analyst-cant-ignore-celldex-stock-cldx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628726627","title":"Celldex Therapeutics Shares up 0.8% After Barclays Double Upgrades to Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2628726627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628726627?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:36","pubTimestamp":1776692207,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nL4N4130Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628257627","title":"Celldex Therapeutics Raised to Overweight From Underweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2628257627","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628257627?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:21","pubTimestamp":1776691260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 20, 2026 09:21 ET (13:21 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628255037","title":"BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, Biogen","url":"https://stock-news.laohu8.com/highlight/detail?id=2628255037","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628255037?lang=en_us&edition=fundamental","pubTime":"2026-04-20 21:05","pubTimestamp":1776690324,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-TopBuild, MDA Space, BiogenWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nL6N4130N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FCX","CVX","HL","CLF","BIIB","USAR","CDE","JEF","LION","QXO","CCL","JPMO","GLSI","PASG","MRVL","WHR","DVN","NEMG","XOMX","SF","AALG","NEM","GTLB","NKTR","XOM","BHP.AU","FRMI","ATAI","CCL.UK","BLD","RIO.UK","RIO.AU","AMZN","GHRS","META","RBC","XOMO","DFTX","SRFM","SCCO","AAL","SOC","CMPS","ASTS","BMI","OKTA","OXY","AU","CLDX","FCXG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628728864","title":"BUZZ-Celldex climbs after Barclays' double upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2628728864","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628728864?lang=en_us&edition=fundamental","pubTime":"2026-04-20 20:10","pubTimestamp":1776687019,"startTime":"0","endTime":"0","summary":"BUZZ-Celldex climbs after Barclays' double upgrade** Shares of drug developer Celldex Therapeutics CLDX.O climb 4% to $35.95 premarket ** Barclays upgrades the stock to \"overweight\" from \"underweight\"; hikes PT to $45 from $24 ** New PT represents a 30.2% upside to stock's last close ** Brokerage says clinical trial of co's drug barzolvolimab's filled up with patients six months ahead of schedule, \"which at a minimum speaks to the demand and enthusiasm for the asset\"** Barzolvolimab is being developed as a treatment for chronic spontaneous urticaria , a skin condition causing chronic hives** Barclays raises probability of success estimate for Barzolvolimab to 85% from 65% and projects $1.4 billion in peak sales, with additional revenue potential from expanded indications in related conditions** As of last close, CLDX up 27.2% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nL4N4130SU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628741493","title":"Celldex Therapeutics : Barclays Raises to Overweight From Underweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2628741493","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628741493?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:24","pubTimestamp":1776680679,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nAZN4SRN4P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.0228},{"period":"1month","weight":-0.0221},{"period":"3month","weight":0.0445},{"period":"6month","weight":0.1632},{"period":"1year","weight":0.5842},{"period":"ytd","weight":0.1572}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.475,"avgChangeRate":0.004594},{"month":4,"riseRate":0.5,"avgChangeRate":0.003159},{"month":5,"riseRate":0.275,"avgChangeRate":-0.021672},{"month":6,"riseRate":0.5,"avgChangeRate":0.145989},{"month":7,"riseRate":0.425,"avgChangeRate":-0.012999},{"month":8,"riseRate":0.375,"avgChangeRate":-0.027935},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}